PHARMACY

Synergy Medical continues rank among Canada’s top 500 companies

BY Sandra Levy

Longueuil, Quebec, Canada-based Synergy Medical placed No.397 among Canadian Business and Maclean’s 30th annual list of Canada’s fastest-growing companies.

Synergy Medical designs, manufactures and installs automated systems, which allows pharmacies to efficiently and accurately prepare compliance packs — specialized pill boxes that enable patients to adhere to their medication regimens.

The Growth 500 ranks Canadian businesses on five-year revenue growth. Growth 500 winners are profiled in a special print issue of Canadian Business published with Maclean’s magazine and online at CanadianBusiness.com and Growth500.ca.

“The 2018 Growth 500 companies are truly remarkable. Demonstrating foresight, innovation and smart management, their stories serve as a primer for how to build a successful entrepreneurial business today,” Growth 500’s program manager said. “As we celebrate 30 years of Canada’s Fastest-Growing Companies program, it’s encouraging to see that entrepreneurship is healthier than ever in this country.”

“Synergy Medical is honored to be on the Growth 500 list, and proud to have made such a leap in 2018,” Synergy Medical’s CEO Jean Boutin said. “Our ranking reflects the commitment of our employees, the quality of our products, and our desire to remain at the forefront by continuing to meet and surpass our customers’ expectations. I wish to thank each member of the Synergy Medical team for their contribution, as well as each of our customers for putting their trust in this team.”

Synergy Medical has installed close to 400 SynMed and SynMed Ultra systems throughout North America and in Europe, in independent pharmacies as well as in centralized production facilities for pharmacy chains. The client list in automated dispensing includes the largest pharmacy chains in Canada at Shoppers Drug Mart and the United States at CVS/Omnicare.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

DSNTV: Canally discusses Compliance Team’s role in quality care validation

BY DSN STAFF

At the 2018 National Association of Chain Drug Stores Total Store Expo held in Denver at the end of August, Drug Store News sat down with Sandy Canally, the president and CEO of The Compliance Team.

Canally discussed the company’s early beginnings in 1998, and how it’s now coming up on its 25th anniversary in 2019.

In addition, she explained the importance of being a quality validator, and ensuring exemplary service to consumers in everything from the day-to-day tasks to immunizations, as well as both the storage and dispensing of drugs.

She also explained why The Compliance Team wants to be thought of as a quality provider, noting that to consumers, payers and referral services, seeing a third party come in and validate that a pharmacy is at its highest level of quality ensures patients are being served the way they deserve to be.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

AstraZeneca gets FDA green light for Lumoxiti

BY Sandra Levy

The Food and Drug Administration has given the nod to AstraZeneca’s Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL.

“Lumoxiti fills an unmet need for patients with hairy cell leukemia whose disease has progressed after trying other FDA-approved therapies,” Richard Pazdur, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said. “This therapy is the result of important research conducted by the National Cancer Institute that led to the development and clinical trials of this new type of treatment for patients with this rare blood cancer.”

HCL is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. HCL is named after these extra B cells which look “hairy” when viewed under a microscope. As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced.

The FDA granted this application Fast Track and Priority Review designations. Lumoxiti also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?